Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Sales: LOQTORZI net sales increased by 61% year-over-year, totaling $11.8 million for Q1 2026, down slightly from $12.4 million in Q4 2025, attributed to typical seasonal trends and severe weather impacts.

Revenue Guidance: The company projects reaching $15 million per quarter in 2026, $30 million to $35 million per quarter in 2027, and a peak of $44 million per quarter by 2028, translating to an annualized $175 million.

Operating Expenses: R&D expenses decreased to $21.5 million from $24.4 million year-over-year, while SG&A expenses fell to $23.1 million from $26 million, reflecting cost management and the exit from the biosimilar business.

Cash Position: Total cash, cash equivalents, and investments at the end of the quarter were $167 million, down from $172.1 million at year-end, but sufficient to fund ongoing studies through 2026 and 2027.

2Strategic Updates and Business Highlights

Product Pipeline: The company is focusing on LOQTORZI, a PD-1 inhibitor, and advancing its pipeline assets, including casdozokitug and tagmokitug, across various cancer indications.

Clinical Development: Successful accrual in the CATALYST-202 study for casdozokitug in hepatocellular carcinoma, with initial data expected mid-year. Tagmokitug is being explored in multiple cohorts for head and neck and gastrointestinal cancers.

Commercial Strategy: Increased visibility into treatment patterns through claims data, targeting education on NCCN guidelines to reduce off-label PD-1 use, and expanding the inside sales team to enhance community outreach.

3Forward Guidance and Outlook

The company maintains a positive outlook for revenue growth, expecting a return to growth in LOQTORZI sales in subsequent quarters after Q1's seasonal decline.

Continued focus on driving demand through enhanced commercial strategies and targeted investments, with a goal of achieving significant market penetration in the oncology space.

4Bad News, Challenges, or Points of Concern

Seasonal Impact: Severe winter weather affected patient treatment cycles, leading to a decline in sales despite strong new patient starts.

Competitive Landscape: The evolving CCR8 antibody market poses risks, as some competitors are halting programs due to safety and efficacy concerns, while others advance, creating a mixed competitive environment.

Clinical Development Risks: The success of ongoing trials is crucial, and any setbacks could impact future revenue projections and market positioning.

5Notable Q&A Insights

Treatment Duration: The average duration of LOQTORZI treatment is increasing, particularly among first-line patients, with 75%-80% of new patients coming from the metastatic setting.

Data Expectations: Investors should look for overall response rates and clinical benefit from upcoming tagmokitug data readouts, with a focus on durability and potential regulatory pathways.

Market Dynamics: There is recognition of the need to address the competitive landscape, particularly with emerging therapies in head and neck cancer, and the importance of differentiating LOQTORZI from off-label PD-1 use. Overall, Coherus Oncology is navigating a complex landscape with a strong pipeline and strategic focus on growth, but faces challenges from market dynamics and operational execution that will require careful management.